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HypertensionNeuronal nitric oxide synthase (NOS1 or nNOS) exerts negative inotropic and positive lusitropic effects
through Ca2+ handling processes in cardiac myocytes from healthy hearts. However, underlying mechanisms
of NOS1 in diseased hearts remain unclear. The present study aims to investigate this question in angiotensin
II (Ang II)-induced hypertensive rat hearts (HP). Our results showed that the systolic function of left ventricle
(LV) was reduced and diastolic function was unaltered (echocardiographic assessment) in HP compared to
those in shams. In isolated LV myocytes, contraction was unchanged but peak [Ca2+]i transient was increased
in HP. Concomitantly, relaxation and time constant of [Ca2+]i decay (tau) were faster and the phosphorylated
fraction of phospholamban (PLN-Ser16/PLN) was greater. NOS1 protein expression and activity were in-
creased in LV myocyte homogenates from HP. Surprisingly, inhibition of NOS1 did not affect contraction
but reduced peak [Ca2+]i transient; prevented faster relaxation without affecting the tau of [Ca2+]i transient
or PLN-Ser16/PLN in HP, suggesting myoﬁlament Ca2+ desensitization by NOS1. Indeed, relaxation phase of
the sarcomere length–[Ca2+]i relationship of LV myocytes shifted to the right and increased [Ca
2+]i for
50% of sarcomere shortening (EC50) in HP. Phosphorylations of cardiac myosin binding protein-C
(cMyBP-C282 and cMyBP-C273) were increased and cardiac troponin I (cTnI23/24) was reduced in HP. Impor-
tantly, NOS1 or PKG inhibition reduced cMyBP-C273 and cTnI23/24 and reversed myoﬁlament Ca2+ sensitivity.
These results reveal that NOS1 is up-regulated in LV myocytes from HP and exerts positive lusitropic effect by
modulating myoﬁlament Ca2+ sensitivity through phosphorylation of key regulators in sarcomere.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Systemic hypertension is one of the major risk factors for develop-
ing cardiac hypertrophy and heart failure due to mechanical and neu-
rohormonal (e.g. increased renin–angiotensin system) disturbance of
intracellular Ca2+ handling and myoﬁlament responses to Ca2+ in
the myocardium [1,2]. Nitric oxide (NO) has been implicated to be
one of the major inﬂuences of cardiac contractile function in bothulNationalUniversity, College of
public of Korea. Tel.: +82 2 740
).
nc. Open access under CC BY-NC-ND lihealthy and diseased hearts [3,4]. Recently, neuronal nitric oxide
synthase (nNOS or NOS1) protein expression and activity are shown
to be increased in hypertrophic or failing LV myocardium both in an-
imal models and in humans [5,6], indicating a signiﬁcant role NOS1
plays in regulating cardiac function. Indeed, NOS1 has been demon-
strated to be instrumental in preventing the deterioration of systolic
and diastolic dysfunction in myocardial infarction-induced or ische-
mic HP [7,8]. However, mechanisms mediating the effect of NOS1
on myocyte contractility in diseased heart remain unidentiﬁed.
Using NOS1 gene knockout mice model, our previous work and
that of others have shown that NOS1 in the sarcoplasmic reticulum
(SR) attenuates cardiac contraction by reducing peak L-type Ca2+
currents (ICa-L) [9,10] or by modulating SR Ca2+ loading following
s-nitrosylation of ryanodine receptors and increasing Ca2+ leak
[11,12]. Furthermore, NOS1 facilitates basal cardiac relaxation pre-
dominantly by increasing phospholamban Ser16 phosphorylationcense.
108 C.Z. Jin et al. / Journal of Molecular and Cellular Cardiology 60 (2013) 107–115(PLN-Ser16) and SERCA activity, which subsequently improves Ca2+
reuptake into SR [13,14]. It is plausible to suggest that NOS1
up-regulation in hypertrophic or failing myocardium may strengthen
its negative inotropic and positive lusitropic effects by regulating in-
tracellular Ca2+ transients ([Ca2+]i) secondary to reduced ICa-L densi-
ty and increased PLN-Ser16. However, despite the fact that NOS1 is
up-regulated and is translocated from SR to the caveolae (where
ICa-L resides) [5], ICa-L density is genuinely unaffected [15,16] in hyper-
trophic or failing myocardium. Furthermore, PLN-Ser16 is signiﬁcantly
reduced and SERCA activity is impaired [17], suggesting that NOS1
may regulate myocardial contractility via a mechanism that is differ-
ent from ICa-L or PLN-Ser16 in diseased myocardium.
In the present study, we aim to examine the mechanisms of NOS1
in regulating contraction and relaxation in LV myocytes from angio-
tensin II (Ang II)-induced systematic hypertensive rats. Our results
reveal that NOS1 is up-regulated in LV myocytes from hypertensive
heart and modulates myoﬁlament Ca2+ sensitivity by increasing
PKG-dependent phosphorylations of cMyBP-C-Ser273 and cTnI23/24.
This novel mechanism is important in understanding NOS1 regulation
of myocardial contractile function in hypertension.
2. Methods & materials
Detailed information of the Methods andmaterials can be found in
Online Supplementary Data.
2.1. Animals
Sprague–Dawley rats (12 weeks old, male) were subjected to Ang
II infusion subcutaneously using osmotic minipump for 4 weeks, and
were paired with a sham-operated group. Blood pressure was mea-
sured using Non-Invasive Blood Pressure System, tail-cuff method
(CODA).
2.2. Functional assessment of the rat hearts by echocardiography
Transthoracic echocardiogram was performed in Ang II (4 weeks)
and in shams with a portable echocardiographic system (Vivid Q Porta-
ble Ultrasound Machine; GE Healthcare, Pittsburgh, PA, USA) equipped
with a 10-MHz transducer (10S-RS; GEHealthcare, Pittsburgh, PA, USA).
2.3. Immunoblotting
Immunoblots were performed in rat LV myocyte lysates using spe-
ciﬁc antibodies against NOS1 (Santa Cruz) and NOS3 (BD Transduction
Laboratories), total PLN (Afﬁnity Bioreagents) and its Ser16 phosphory-
lated fraction (PLN-Ser16, Upstate), total and phosphorylated fraction of
cardiac troponin I: cTnI (Santa Cruz) and cTnI23/24 (Cell Signaling), total
and phospho-speciﬁc cMyBP-C antibodies [18].
3. Results
3.1. Systolic and diastolic blood pressures and LV contractile functions in
HP rats
Both systolic and diastolic blood pressures were increased 1 week
after Ang II infusion (125 ng/min/kg) and continuously increased up to
the period studied (Fig. 1A). At 4 weeks, systolic blood pressure was
127.8 ± 2.9 mm Hg in shams vs. 156.6 ± 4.9 mm Hg with Ang II
(P b 0.001, n = 26); diastolic blood pressure was 92.8 ± 2.8 mm Hg in
shams vs. 113.4 ± 4.7 mm Hg with Ang II (P b 0.001, n = 26). Heart
rate was signiﬁcantly lower in hypertensive rats (HP, heart rate, beats/
min: 457.1 ± 5.8 in shams and 426.7 ± 10.6 in HP, P = 0.02, n = 26
and n = 26). Autopsy weight of LV myocardium and dimensions of LV
myocytes were measured to assess whether myocardial hypertrophy
was induced by systemic hypertension in these rats. As shown inTable 1, heart weight, heart/body weight ratio or average width of LV
myocytes was not increased in HP (heart weight in g, 1.98 ± 0.07 in
shams vs. 2.10 ± 0.08 in HP, P = 0.5, n = 16 and 18; heart/bodyweight
ratio × 100%, 0.53 ± 0.02% in shams vs. 0.57 ±0.02% in HP, P = 0.2,
n = 16 and n = 18; LV myocyte width, μm, 26.1 ± 0.35 in shams vs.
26.6 ± 0.35 in HP, P = 0.3, n = 197 and n = 210), the slack length of
sarcomere was decreased (P = 0.005, n = 197 and n = 210).
Fig. 1B is the representative echocardiograms of shams and HP and
Table 2 shows average results. None of the geometrical parameters of
LV were affected by Ang II treatment at the time points studied
(Table 2). However, LVEF and LVFS were signiﬁcantly lower in Ang
II group (LVEF was 61.83 ± 3.66% in Ang II rats vs. 72.5 ± 2.08% in
shams, P = 0.03, n = 6; LVFS was 29.83 ± 2.5 vs. 37.17 ± 1.82%,
P = 0.04, n = 6, Fig. 1C), indicating contractile dysfunction in this
group. However, despite the fact that blood pressure is signiﬁcantly
increased in Ang II rats, diastolic parameters including E velocity, A
velocity, E/A ratio, E′ velocity and E/E′ ratio were not different be-
tween the two groups (Table 2). These results demonstrate that Ang
II infusion induced hypertension in rats; at 4 weeks, systolic function
was impaired whereas diastolic function was maintained.
3.2. Protein expression and activity of NOS1 in LV myocytes from HP rats
We detected whether NOS1 is up-regulated in LV myocyte ho-
mogenates from HP rats. As shown in Figs. 2A & B, NOS1 protein ex-
pression was signiﬁcantly increased (P = 0.03 compared to that in
shams, n = 9 and 9). Conversely, NOS3 (eNOS) protein expression
was signiﬁcantly reduced (P = 0.004, n = 8 and 8, Figs. 2A & B).
To determine whether increased NOS1 protein expression in LV
myocyte homogenate is associated with its greater activity, we com-
pared NOS1 production of NO (nitrite content) between the groups.
As shown in Fig. 2C, NO production was signiﬁcantly greater in HP com-
pared to shams (P = 0.02, n = 18and18). Pre-treatment of LVmyocytes
with selective and potent NOS1 inhibitors, S-methyl-L-thiocitrulline
(SMTC, 100 nM, 30 min) or vinyl-l-N-5-(1-imino-3-butenyl)-l-ornithine
(L-VNIO, 100 μM, 30 min) reduced NO production in both groups (in
shams, Ctr vs. SMTC, P b 0.001; Ctr vs. L-VNIO, P = 0.04; n = 18 for
each group; in HP, Ctr vs. SMTC, P b 0.001 & Ctr vs. L-VNIO, P = 0.002,
n = 20 and n = 18, 18 & 14, respectively, Fig. 2C). In the presence of
NOS1 inhibitors, NO levelwas no longer different between the twogroups
(P = 0.2, between SMTCs and P = 0.97 between L-VNIOs). These results
suggest that NOS1 is the isoform that is up-regulated and contributes to
the production and the maintenance of NO in cardiac myocytes from HP
rats.
3.3. NOS1 regulation of LV myocyte contraction and relaxation
Next, we testedwhether up-regulation of NOS1 in LVmyocytes from
HP is associatedwith its greater effects onmyocyte contractile function.
Figs. 3A & B showed that LVmyocyte relaxation was signiﬁcantly faster
in HP compared to that in shams (time to 50% relaxation, TR50,
P b 0.001, n = 183 and 237) butmyocyte contractionwas not different
between the groups (amplitude of sarcomere shortening, P = 0.7, n =
183 and 237, Figs. 3A & C). Inhibition of NOS1 (SMTC, 100 nM) did not
affectmyocyte contraction (amplitude of sarcomere shortening, P =0.6
between control and SMTC in shams; P = 0.5 between control and
SMTC in HP, n = 183 vs. 67 and n = 237 vs. 85, Figs. 3A & C). L-type
Ca2+ current (ICa-L) density and its response to SMTC were similar be-
tween the groups (peak ICa-L density at 0 mV was −6.70 ± 0.52 pA/pF
in shams and was −6.87 ± 0.43 pA/pF in HP, P = 0.8, n = 16 and
n = 30; 9.07 ± 0.64 pA/pF with SMTC in shams and was −8.39 ±
0.42 pA/pF with SMTC in HP, n = 10 and 23, P = 0.36).
In contrast, SMTC signiﬁcantly prolonged LV myocyte relaxation
both in shams (TR50, P = 0.03, n = 183 and 67, Fig. 3B) and in HP
(TR50, P b 0.001, n = 237 and 85, Fig. 3B) and abolished the difference
in relaxation between two groups (P = 0.8). Similar to SMTC, L-VNIO
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Fig. 1. Blood pressure changes and echocardiograph assessment of LV contractility following Ang II treatment. A: Time course of the mean systolic (left) and diastolic (right) blood
pressures in Ang II-rats vs. shams. High blood pressure develops from 1 week infusion with Ang II and continuously increases until 4 weeks. B. Representative echocardiograph
images of LV internal dimension (diastole and systole) in M-mode, parasternal short-axis views of a shams (left) and Ang II-rats (right). C. LV ejection fraction and LV fractional
shortening were signiﬁcantly reduced in Ang II-rats.
Table 2
Echocardiographic parameters 4 weeks after Ang II-treatment in vivo.
Sham (n = 6) HP (n = 6) P value
ISVd 0.15 ± 0.02 0.15 ± 0.02 1.00
IVSs 0.23 ± 0.02 0.22 ± 0.02 0.55
LVIDd 0.8 ± 0 0.83 ± 0.03 0.34
LVIDs 0.5 ± 0.03 0.57 ± 0.03 0.14
109C.Z. Jin et al. / Journal of Molecular and Cellular Cardiology 60 (2013) 107–115(100 μM) failed to affect cell shortening (amplitude of sarcomere short-
ening, P = 0.2 between control and L-VNIO in shams; P = 0.11 be-
tween control and L-VNIO in HP, n = 71 vs. 22 and n = 84 and 40)
but prolonged relaxation in both shams and inHP and abolished the dif-
ference between the groups (TR50 in ms: 36.9 ± 8.5 in shams and
35.6 ± 7.2 in HP, P = 0.5, n = 22 and 40).
3.4. NOS1 regulation of intracellular Ca2+ transients
Interestingly, peak and diastolic [Ca2+]i were elevated (F360/F380
ratio, P b 0.001 & P = 0.04, n = 51 and 40) and time constant ofTable 1
Body weight, heart weight and LV myocyte dimensions in sham and hypertensive rats.
Sham (n) Hypertension (n) P value
Body weight (g) 372.5 ± 5.12
(20)
359.1 ± 4.10⁎
(23)
0.046
Heart weight (g) 1.98 ± 0.07
(16)
2.10 ± 0.08
(18)
0.50
Heart weight / body weight × 100% 0.53 ± 0.02%
(16)
0.57 ± 0.02%
(18)
0.17
Sarcomere length (μm) 1.84 ± 0.003
(197)
1.82 ± 0.004⁎
(210)
0.005
Width (μm) 26.1 ± 0.35
(197)
26.6 ± 0.35
(210)
0.33
Values are expressed as means ± SEM.
⁎ P b 0.05.[Ca2+]i decay (tau) was reduced in LV myocytes from HP compared to
those from shams (P b 0.001, Figs. 4C & D). Inhibition of NOS1 with
SMTC reduced peak [Ca2+]i in HP (P = 0.002, n = 40 and 33) butLVPWd 0.18 ± 0.02 0.2 ± 0 0.34
LVPWs 0.27 ± 0.02 0.28 ± 0.02 0.55
LVEF, % 72.5 ± 2.08 61.83 ± 3.66⁎ 0.03
LVFS, % 37.17 ± 1.82 29.83 ± 2.5⁎ 0.04
LV mass 1.40 ± 0.25 1.50 ± 0.19 0.59
E velocity 0.65 ± 0.06 0.66 ± 0.05 0.88
A velocity 0.46 ± 0.06 0.48 ± 0.05 0.87
E/A ratio 1.53 ± 0.25 1.56 ± 0.29 0.94
E′ velocity 0.04 ± 0.005 0.04 ± 0.012 0.95
E/E′ ratio 17.92 ± 2.30 20.12 ± 6.19 0.72
IVSd: IntraVentricular Septum Diastole; IVSs: IntraVentricular Septum Systole; LVIDd
LV Inner Diameter Diastole; LVIDs: LV Inner Diameter Systole; LVPWd: LV posterior
Wall Diastole; LVPWs: LV Posterior Wall Systole; LVFS, %: LV fractioning shortening
was calculated as 100 × (LVEDD − LVESD) / LVEDD; LVEF, %: LV ejection fraction
was determined as 100 × (LVEDD3 − LVESD3) / LVEDD3. LV mass was calculated as
1.04 × [(LVEDD + PW + IVS)3 − LVEDD3] × 0.8 + 0.6.
Values are expressed as means + SEM.
⁎ P b 0.05.
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signiﬁcantly reduced in HP. C. NO production (relative to control) was signiﬁcantly increased in LV myocytes from HP. Both SMTC and L-VNIO blocked NO production in shams and
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peak [Ca2+]i was signiﬁcantly higher in shams compared to that in HP
in the presence of SMTC (P b 0.001, n = 50 and 36, Figs. 4B & C).rtC
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111C.Z. Jin et al. / Journal of Molecular and Cellular Cardiology 60 (2013) 107–115Surprisingly, tau of [Ca2+]i decay was unaffected by SMTC in HP
(Ctr vs. SMTC, P = 0.04, n = 40 and 33, Fig. 4D). In addition, SMTC fa-
cilitated tau of [Ca2+]i decay in shams (P = 0.003 between Ctr and
SMTC, n = 50 and 35, Fig. 4D) and abolished the difference between
sham and HP (P = 0.7, Fig. 4D).
Next, we testedwhether PLN-Ser16 is increased in LVmyocytes from
HP and contributes to faster tau of [Ca2+]i decay and whether NOS1 af-
fects PLN-Ser16. As shown in Fig. 4E, total PLN protein was reduced and
PLN-Ser16 was signiﬁcantly increased in HP (P = 0.02 and P = 0.028,
respectively, n = 6 and n = 6), which resulted in signiﬁcantly greater
PLN-Ser16/PLN ratio (P = 0.04, Fig. 4F). Unexpectedly, SMTC or PKG in-
hibitor, KT5823 (1 μM) failed to suppress the increase of PLN-Ser16 in
HP (P = 0.05 between control and SMTC in HP, n = 6, n = 6, Figs. 4E
& F; P = 0.05 between control and KT 5823 inHP, n = 6 and 6). In con-
trast, PKA inhibitor, PKI (1 μM) reduced PLN-Ser16 in HP (P = 0.03,
n = 5 and n = 5) and normalized PLN-Ser16/PLN between the groups
(Data supplements — Fig. 1A). Surprisingly, PKI did not affect LV
myocyte relaxation in HP or tau of [Ca2+]i decay (P = 0.003, n = 32
and n = 10 for relaxation and P = 0.1, n = 40 and n = 22 for tau,
Data supplements — Fig. 1C).
These results suggest that increase in PLN-Ser16 or faster tau of
[Ca2+]i transients is unlikely the underlying mechanisms for NOS1 fa-
cilitation of LV myocyte relaxation in HP. In addition, although NOS1
was responsible for increased peak [Ca2+]i, myocyte contraction was
unaffected by NOS1 inhibition in LV myocytes from HP.
3.5. NOS1 regulation of myoﬁlament Ca2+ sensitivity
The aforementioned results suggest that NOS1 may facilitate LV
myocyte relaxation by reducing myoﬁlament Ca2+ sensitivity in HP. In
order to examine this possibility, we recorded sarcomere shortening/
relengthening and [Ca2+]i transient simultaneously in Fura-2-loaded
LV myocytes from shams and from HP and plotted a phase-plane loop
of sarcomere length vs. [Ca2+]i transient before and after SMTC0.1ratio
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Fig. 4. NOS1 regulation of intracellular Ca2+ transients and PLN-Ser16 in shams and HP rat
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[Ca2+]i decay (tau) was faster in HP. SMTC facilitated tau in shams but exerted no change
PLN-Ser16/PLN-Ser16 ratio in control, SMTC-pre-treated or KT5823-pre-treated LV myocyte h
so the PLN-Ser16/PLN ratio was signiﬁcantly increased in HP. NOS1 with SMTC (100 nM) ditreatment. As shown in Figs. 5A & B, relaxation phase of the sarcomere
length–[Ca2+]i transient relationship shifted to the right in HP; Ca2+
level at 50% sarcomere relengthening (EC50) was signiﬁcantly larger in
this group (P = 0.01 shams vs.HP, n = 21 & n = 21, Fig. 5C), indicative
of myoﬁlament Ca2+ desensitization.
SMTC reversed the rightward-shift of sarcomere length–[Ca2+]i
transient relationship to the left (Fig. 5B) and reduced EC50 in HP
(P = 0.01, n = 21 and 25, Fig. 5C) back to the control level in
shams (Fig. 5C). These results suggest that NOS1 up-regulation is re-
sponsible for myoﬁlament Ca2+ desensitization in HP.
Notably, SMTC shifted the relaxation phase of the sarcomere–
[Ca2+]i transient relationship to the right in shams and increased EC50
(from 0.29 ± 0.02 in control to 0.39 ± 0.13 with SMTC P b 0.001,
n = 21 and n = 22, Figs. 5B & C), suggesting that myoﬁlament Ca2+
sensitivity was reduced by SMTC in this group. Acute NOS1 inhibition
increased NADPH oxidase (or xanthine oxidoreductase) production of
intracellular superoxide and slowed relaxation in LV myocytes [13].
Therefore, we tested whether NOS1 attenuation of intracellular super-
oxide maintains myoﬁlament Ca2+ sensitivity and SMTC reverses it.
As shown in Data supplement — Fig. 2, sarcomere length–[Ca2+]i rela-
tionship and EC50 was no longer different between control and SMTC
after tiron pre-treatment (EC50, P = 0.07, n = 26 and 21). Therefore,
at least in rat LV myocytes, myoﬁlament Ca2+ sensitivity is maintained
by NOS1 modulation of cardiac oxidases in shams.
Recent compelling evidence shows thatmyoﬁlament Ca2+ sensitivity
affects intracellular Ca2+ homeostasis by changing Ca2+ buffering in car-
diac myocytes; e.g. enhanced myoﬁlament Ca2+ sensitivity in TnTmuta-
tion (TnT-179N) increases Ca2+ binding to myoﬁlaments and reduces
systolic [Ca2+]i and slows the speed of Ca2+ decline [19], similar to the
effects reportedwith exogenous Ca2+ buffer, NP-EGTA [20]. Accordingly,
we examined whether reducedmyoﬁlament Ca2+ sensitivity by NOS1 is
responsible for greater peak [Ca2+]i and faster tau of [Ca2+]i decay in LV
myocytes fromHP.We compared the amplitude and the decay kinetics of
[Ca2+]i transients before and after NOS1 inhibition in shams and in HPMTC
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Fig. 5. NOS1 regulation of myoﬁlament Ca2+ sensitivity in shams and in HP. A. C. Simultaneous recordings of LV myocyte sarcomere shortening/relengthening and intracellular
Ca2+ transients in the absence (left) and presence (right) of SMTC. B. Phase-plane loop of sarcomere shortening/relengthening vs. [Ca2+]i transient. The relaxation phase of the
loop shifted to the right in HP compared to that of shams. SMTC pre-treatment reversed the rightward shift of the sarcomere shortening/relengthening and [Ca2+] relationship
in HP but induced rightward shift in shams. D. [Ca2+]i (Fura-2 ratio) for 50% sarcomere relengthening is larger in HP compared to shams. SMTC increased EC50 in shams but reduced
it in HP.
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butanedione monoxime (BDM), which is well known to reduce myoﬁla-
ment Ca2+ sensitivity. As expected, 30 min pre-incubation with BDM
(10 mM) abolished LV myocyte shortening in both groups. However,
peak [Ca2+]i was increased and tau of [Ca2+]i decay was signiﬁcantly re-
duced in shams in the presence of BDM (P b 0.001, P = 0.001, n = 53 &
23, Data supplement — Fig. 3). In contrast, BDM did not affect peak
[Ca2+]i or tau of [Ca2+]i decay in both shams and HP in the presence
or absence of SMTC (P = 0.9 & P = 0.8, n = 23 and 13 Data
supplement — Fig. 3). These results suggest that myoﬁlament Ca2+
desensitization by NOS1 increases the amplitude of [Ca2+]i and
facilitates the decay kinetics of [Ca2+]i in LV myocytes from HP.
3.6. Mechanism of NOS1 modulation of myoﬁlament Ca2+ sensitivity
Next, we determined molecular mechanisms mediating NOS1 re-
duction of myoﬁlament Ca2+ sensitivity in LV myocytes from HP rats.
We have examined whether PKG-dependent signaling mediates NOS1
reduction of myoﬁlament Ca2+ sensitivity and faster relaxation in HP.
As shown in Fig. 6, PKG inhibitor, KT5823 (1 μM) shifted the relaxation
phase of sarcomere length–[Ca2+]i relationship to the left in HP LV
myocytes (Figs. 6A & B) and reduced EC50 (P = 0.04, n = 21 & 19,
Fig. 6C) and abolished the difference between sham and HP.
Exogenous NO donor has been shown to facilitate LVmyocyte relax-
ation by inducing PKG-dependent increase in cTnI phosphorylation
(cTnI23/24) andmyoﬁlament Ca2+desensitization in rats [21]. Therefore,
we examined whether cTnI23/24 is increased following NOS1
up-regulation in LV myocytes from HP rats and whether this effect is
mediated by PKG. To our surprise, total cTnI protein expression was sig-
niﬁcantly increased and cTnI23/24 was signiﬁcantly reduced, which
resulted in decreased cTnI23/24/cTnI ratio in HP (0.41 ± 0.06 vs.1.27 ± 0.15 in HP, P b 0.0001, n = 10 & 10). SMTC pre-incubation did
not affect cTnI23/24 in shams (cTnI23/24 ratio: 1.27 ± 0.15 in control vs.
1.16 ± 0.21with SMTC, P = 0.67, n = 10 & 10, Fig. 7A) but signiﬁcant-
ly reduced it inHP (P = 0.02, n = 10&10, Fig. 7B). KT5823 signiﬁcantly
reduced cTnI23/24 in sham and in HP (P b 0.001, n = 10 & 10, Fig. 7B).
Cardiac myosin binding protein-C (cMyBP-C) is an important sarco-
mere protein that maintains the interaction and the arrangement
between actin and myosin. Phosphorylation of cMyBP-C (at putative
phosphorylation sites, Ser-273, Ser-282 and Ser-302, mouse) is essential
for the force and kinetics of contraction in cardiac myocytes [22]. There-
fore, we examined whether cMyBP-C is phosphorylated by NOS1
up-regulation in HP. Total cMyBP-C protein expression was signiﬁcantly
increased in HP compared to those in shams (P b 0.001, n = 11 and
11, Data supplement — Fig. 4). Two putative phosphorylation sites,
cMyBP-C Ser282 and cMyBP-C Ser273 were signiﬁcantly increased in HP
compared to those in shams (P b 0.001, P b 0.0001, n = 6 and 7, respec-
tively, Data supplement — Fig. 3 and Figs. 7C & D). However, cMyBP-C
Ser282 was not sensitive to SMTC, PKI or KT5823 (P = 0.007, P = 0.02
and P = 0.01, n = 6, respectively, Data supplement — Fig. 3A & B). In
contrast, cMyBP-C Ser273 was reduced by SMTC, PKI and KT5823 (P =
0.02, P = 0.02 and P =0.05, n = 5, 5 and 5, respectively, Figs. 7C & D).
These results reveal that PKG-dependent cTnI23/24 and PKA and
PKG-dependent cMyBP-C Ser273 may be the potential targets of
NOS1 whose post-transcriptional modiﬁcation modulates myoﬁla-
ment Ca2+ sensitivity and facilitates LV myocyte relaxation in hyper-
tensive rat hearts.
3.7. Discussion
Our present study demonstrates that NOS1 is the predominant
isoform of NOS that is up-regulated and contributes to myocardial
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that NOS1 facilitates LV myocyte relaxation by phosphorylating key
sarcomere proteins (e.g. cTnI23/24 and cMyBP-C273) and by reducing
myoﬁlament Ca2+ sensitivity in HP. Modulation of myoﬁlament
Ca2+ sensitivity by NOS1 may, in turn, regulate Ca2+ homeostasisA C
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phosphorylated fraction of cMyBP (cMyBP-C Ser273) in LV myocytes before and after NOS1/P
increased in HP compared to those in shams. NOS1, PKA and PKG inhibition signiﬁcantly reduand maintain LV myocyte contraction. Evidences that support the
conclusions are: 1) NOS1 protein expression and NOS1-derived NO
were increased whereas NOS3 protein was signiﬁcantly reduced in
LV myocytes from HP rats. 2) LV myocyte contraction was unchanged
but [Ca2+]i transient was signiﬁcantly increased in HP rats. In these
LV myocytes, inhibition of NOS1 reduced [Ca2+]i transient but did
not change myocyte contraction; ICa-L was not affected by NOS1
up-regulation. 3) LV myocyte relaxation was faster in HP LV myocytes,
which was accompanied by greater PLN-Ser16/PLN and faster decay ki-
netics of [Ca2+]i transient. Unexpectedly, NOS1 reversed faster relaxa-
tion without affecting the tau of [Ca2+]i transient decay or PLN-Ser16
increment. 4) Relaxation phase of sarcomere length–[Ca2+]i relation-
ship shifted to the right and [Ca2+]i, that is required for 50% sarcomere
relengthening (EC50), was larger in HP. Both effects were reversed by
NOS1 and PKG inhibition. 5) Myosin ATPase inhibitor, BDM, which re-
duces myoﬁlament Ca2+ sensitivity, increased [Ca2+]i transient ampli-
tude and facilitated the kinetics of [Ca2+]i transient decline in shams
but exerted no effect on these parameters in HP. 6) NOS1 and PKG inhi-
bition signiﬁcantly decreased cTnI23/24 and cMyBP-C Ser273 (but not
cMyBP-C Ser282) and reversed myoﬁlament Ca2+ sensitivity and relax-
ation in HP. PKA inhibition decreased cMyBP-C Ser273; cMyBP-C Ser282
was insensitive to either KT5823 or PKI.
Ca2+ plays a central role in regulating contraction and relaxation.
Accordingly, activities of Ca2+ handling proteins involve in excitation–
contraction coupling have been attributed to NOS1 regulation of
myocardial contractility [9,10,12,13]. However, our present results
reveal that myoﬁlament Ca2+ sensitivity becomes an important
downstream mechanism of NOS1 and contributes signiﬁcantly to
the positive lusitropic effect of NOS1 in hypertensive myocardium.
Our results are in line with previous reports demonstrating that NO
is involved in the regulation of myoﬁlament Ca2+ sensitivity in car-
diac myocytes; e.g. exogenous NO donors (SNAP or DEA NONOate)
have been shown to reducemyoﬁlament Ca2+ sensitivity andmod-
ulatemyocyte contraction and facilitate relaxation [21,23]. Similar-
ly, cardiomyocyte-speciﬁc overexpression and activation of NOS3
suppressed myoﬁlament response to intracellular Ca2+, facilitated ki-
netics of both contraction and relaxation and reduced contraction in
the left ventricle [21,23,24]. This is the ﬁrst report to show that NOS1cMyBP-C
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source of enhanced NO (rather than NOS3) to exert the positive
lusitropic effect by modulating myoﬁlament Ca2+ sensitivity. However,
this mechanism is in contrast to its role in myoﬁlament Ca2+ sensitivity
and myocyte relaxation in healthy myocardium. Albeit the predominant
mechanism of NOS1 in lusitropy is through increasing PLN-Ser16 and
Ca2+ reuptake via SERCA, NOS1 under basal conditions was shown to
augmentmyoﬁlament Ca2+ sensitivity and promote force–frequency re-
sponse [25]; conversely, NOS1 gene deletion was associated withmyoﬁl-
ament Ca2+ desensitization and impaired force–frequency response [25].
In this study, increased xanthine oxidoreductase (XOR) production of su-
peroxide has been attributed to the modulation of myoﬁlament Ca2+
sensitivity since allopurinol reversed the effects of NOS1 inhibition. Con-
sistent to these results, we have also found that NOS1 inhibition with
SMTC shifted sarcomere length–[Ca2+]i relationship to the right and in-
creased EC50 in sham LV myocytes (Figs. 5B & D). Superoxide scavenger,
tiron, prevented such amodulation by SMTC, suggesting the involvement
of oxidative regulation of myoﬁlament Ca2+ desensitization under these
settings. Our previous results have shown that intracellular superoxide
is increased fromNADPH oxidase after NOS1 inhibition [14]; it is possible
that NOS1 modulation of XOR and/or NADPH oxidase activities is impor-
tant in maintaining myoﬁlament Ca2+ sensitivities in cardiac myocytes.
Similar NO-dependent augmentation of myoﬁlament Ca2+ sensitivity in
normal cardiac myocytes has also been reported recently [26].
The molecular targets of NOS1 in myoﬁlament and its functional
regulation have not been documented before. cTnI has been the “clas-
sic” downstream target of NO that underlies myoﬁlament Ca2+ de-
sensitization following PKG-dependent phosphorylation. Indeed,
NOS1 and PKG inhibition signiﬁcantly reduced cTnI23/24 in HP,
suggesting that cTnI-Ser23/24 maymediate NOS1modulation of myoﬁla-
ment Ca2+ sensitivity. However, basal cTnI23/24 was signiﬁcantly re-
duced and total cTnI protein was increased compared to those in
shams. In line with these results, Su et al. [27] reported recently that
NOS1/NOS3 downregulation was associated with increased cTnI23/24
and reduced cMBP-C282 in cardiac myocytes from dog model of
Duchenne muscular dystrophy. In fact, whether cTnI phosphorylation
contributes to reduced myoﬁlament Ca2+ sensitivity is still a subject of
debate since both increased and decreased cTnI phosphorylation has
been shown in the failing myocardium where myoﬁlament Ca2+ sensi-
tivity is suppressed [24,25].
Importantly,we present direct evidence to show that cMyBP-C is an-
other potential target of NOS1 that regulates myocardial contraction
and relaxation. In addition, cMyBP-C273 is phosphorylated by both
PKA and PKG, since both PKI and KT5823 reduced cMyBP-C273 in HP,
which is consistent with previous in vitro experiments [28]. Therefore,
cMyBP-C273 could be the functional target of NOS1. However, the spe-
ciﬁc role of cMyBP-C273 and its upstream regulators in the myocardium
remain largely unknown. The relative contributions of each phosphory-
lation site in cMyBP-C and their functional inﬂuence in cardiacmyocyte
are emerging [29]. It is possible that cMyBP-C273 phosphorylation may
regulate cMyBP-C interaction with myosin and actin, thereby myoﬁla-
ment Ca2+ sensitivity. Detailed mechanism of NOS1 regulation of myo-
ﬁlament Ca2+ sensitivity and cardiac contractile function in diseased
heart warrants further investigation.
As expected, NOS1 up-regulation was associated with increased
PLN-Ser16 in LV myocytes from HP rats. However, to our surprise,
NOS1 inhibition with SMTC did not reduce PLN-Ser16 or retard the
speed of Ca2+ reuptake into SR, despite the fact that SMTC prevented
faster LVmyocyte relaxation in HP. Furthermore, unlike our previous re-
sult that increased NOS1 protein expression and activity (after Ang II
treatment 3 h) induced PKG-dependent PLN-Ser16, PKG inhibition with
KT5823 did not reduce PLN-Ser16, instead, it was reduced by PKA inhibi-
tion. In fact, we have found that NOS1 regulation of PLN-Ser16 and the
mediating mechanism is a dynamic process: NOS1 increases PLN-Ser16
via PKA-dependent signaling (independent of PKG) in basal→ NOS1 in-
creases PLN-Ser16 via PKG-dependent signaling when upregulated byAng II acutely (independent of PKA)→ NOS1 fails to affect PLN-Ser16 de-
spite the fact that NOS1 is signiﬁcantly upregulated in HP; PLN-Ser16 is
regulated by PKA-dependent signaling (independent of PKG). These re-
sults strongly suggest that in the myocardium under stress, the primary
targets of NOS1 may have shifted from PLN in the SR to cTnI and
cMyBP-C from the myoﬁlament. Alternatively, NOS1 up-regulation may
cause the remodeling of intracellular signaling pathways that exert site
speciﬁc phosphorylation of cTnI or cMyBP-C, possibly due to the changes
in NOS1 localization in deﬁned compartment. Although PLN may not be
directly regulated by NOS1, NOS1modulation of myoﬁlament Ca2+ sen-
sitivity increases the amplitude of [Ca2+]i, which in turn, induces faster
[Ca2+]i decline in LV myocytes, an indirect mechanism to promote
Ca2+ reuptake back into SR. Since PLN inhibition of SERCA is intracellular
[Ca2+]i concentration-dependent (PLN inhibits SERCA at submicromolar
[Ca2+]i but such inhibition weakens at micromolar Ca2+ [30]), it is pos-
sible to speculate that at higher cytosol Ca2+ level (as in HP), PLN re-
lieves its inhibition of SERCA, resulting in negligible effect of PLN-Ser16
on SERCA activity, especially when basal PLN-Ser16 is generally low in
rats (PLN-Ser16/PLN ratio is ~0.2) compared to those in mice [13,31]
and total PLN levelwas signiﬁcantly reduced inHP. Itwould be necessary
for NOS1 to regulate myocardial function through more effective
mechanism.
In conclusion, our results demonstrate that NOS1 is up-regulated
in LV myocytes from systematic HP rats and modulates myoﬁlament
Ca2+ sensitivity by targeting cTnI23/24 and cMyBP-C273. This becomes
a predominant mechanism of NOS1 to facilitate LV myocyte relaxa-
tion under these conditions. Therefore, we propose that this is an im-
portant novel mechanism of NOS1 in protecting the hypertensive
myocardium from diastolic dysfunction.
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